Teva Pharmaceuticals, Teva, Ecopipam, Tourette Syndrome, Pediatric Tourette Syndrome, D1 Receptor, Dopamine, D1AMOND, Phase 2b, Phase 3, FDA

PARSIPPANY, N.J. — October 2, 2026 Teva Pharmaceuticals presented new efficacy and safety data for ecopipam, an investigational selective...